Society for Immunotherapy of Cancer (SITC) 2022

  • -
Location:
,
415 Summer St.
,
Boston, MA 02210

VISIT US AT BOOTH 711

The Society for Immunotherapy of Cancer’s 37th Annual Meeting & Pre-Conference Programs (SITC 2022) provides a multidisciplinary educational and interactive environment focused on improving the outcome for current and future patients with cancer by incorporating strategies based on basic and applied cancer immunotherapy.

NanoString Symposium: Expanding the Power of Spatial Biology

November 10, 11:40 a.m. – 1:10 p.m.

Room 157 at the Boston Exhibition and Convention Center

Spatial-omics Revolution: Innovation Roadmap and Key Applications

Vikram Devgan, PhD, Senior Director, Product Management, NanoString Technologies

Applications of the CosMx Spatial Molecular Imager

Joseph Beechem, PhD, Chief Scientific Officer and Senior Vice President of Research and Development, NanoString Technologies

Spatial Proteogenomics in the Era of Immunotherapy and COVID-19

Arutha Kulasinghe, PhD, NHMRC Research Fellow, The University of Queensland

Precision Oncology in Pancreatic Cancer through Single-cell and Spatial Omics

William Hwang, MD, PhD, Assistant Professor, Harvard Medical School; Principal Investigator, Massachusetts General Hospital; Associate Faculty Member, Broad Institute of MIT and Harvard

Sign up for an AtoMx Experience at our booth

Oral Presentations featuring NanoString Technologies

IDTimePoster titleFirst author
161November 10
11:55 a.m. to 12:55 p.m.
Single-Cell Spatial In situ Transcriptomics Unravels Vulvar HSIL Composition Associated with Complete Response to Therapeutic VaccinationZiena Abdulrahman
951November 11
12:10 to 1:10 p.m.
Spatial Atlases of Immunological Development within the Lymph NodeTyler Hether

Poster Presentations featuring NanoString Technology

IDTimePoster TitleFirst author
25November 10, 2022
11:40 a.m. to 1:10 p.m.
Potential Predictive Biomarkers for BXCL701 in Acute Myeloid Leukemia (AML)Veena Agarwal
99November 10, 2022
11:40 a.m. to 1:10 p.m.
Spatial Insights into Tumor Immune Evasion Illuminated with the CosMx Spatial Molecular Imager PlatformJason Reeves
117November 10, 2022
11:40 a.m. to 1:10 p.m.
High-plex Spatial Proteomic Profiling of Immunotherapy Response Groups in Head and Neck Cancer Identifies Tissue Signatures Associated with Therapy Response Arutha Kulasinghe
127November 10, 2022
11:40 a.m. to 1:10 p.m.
Spatial-specific Gene Signatures Outperform Bulk-mRNA Signatures to Define Resistance to Immunotherapy in Melanoma PatientsThazin Aung
133November 10, 2022
11:40 a.m. to 1:10 p.m.
Spatially Defined Gene Signatures Uncover the Association of Extracellular Matrix Genes with Immunotherapy Resistance in Head and Neck Squamous Cell CarcinomaNiki Gavrielatou
147November 10, 2022
11:40 a.m. to 1:10 p.m.
Comprehensive In Situ Immune Phenotyping with the CosMx High Plex Protein AssayTien M. Phan-Everson
151November 10, 2022
11:40 a.m. to 1:10 p.m.
Using Additional Morphology Markers in NanoString GeoMx Whole Transcriptome Atlas Assay to Assess NSCLC Tumor SubtypeJessica Runyon
161November 10, 2022
11:40 a.m. to 1:10 p.m.
Single-cell Spatial In Situ Transcriptomics Unravels Vulvar HSIL Composition Associated with Complete Response to Therapeutic VaccinationZiena Abdulrahman
167November 10, 2022
11:40 a.m. to 1:10 p.m.
Comprehensive Profiling of Cancer-associated Fibroblasts in CD8+T Cell-exclusive Non-small Cell Lung Cancer Tumor Microenvironments Using the NanoString GeoMX Digital Spatial ProfilerChristina Cho
289November 10, 2022
11:40 a.m. to 1:10 p.m.
Clinical Expansion and Persistence of CAR T-cells: An Essential Biomarker in Need of StandardizationDavid Turicek
513November 10, 2022
11:40 a.m. to 1:10 p.m.
Overcoming Hedgehog Mediated ANTI-PD-1 Resistance in Melanoma through Prostaglandin InhibitionNicholas DeVito
527November 10, 2022
11:40 a.m. to 1:10 p.m.
Spatial Proteomic and Transcriptomic Biomarkers of Response to Immune Checkpoint Inhibitors in Operable Lung CancerJonathan Stauber
569November 10, 2022
11:40 a.m. to 1:10 p.m.
A CIVO Intratumor Microdose Phase 0 Trial of Subasumstat (TAK-981) in Combination with Cetuximab or Avelumab Reveals Type 1 Interferon Induction and Immune Activation in Head and Neck Cancer PatientsJeffrey Houlton
605November 10, 2022
11:40 a.m. to 1:10 p.m.
Neoadjuvant Vidutolimod (Vidu) and Nivolumab (Nivo) Results in MPR and Immune Activation in High-risk Resectable Melanoma (MEL): Final Phase II Clinical Trial ResultsArivarasan Karunamurthy
867November 10, 2022
11:40 a.m. to 1:10 p.m.
Deciphering of Radiotherapy-induced Immunomodulation Effect Synergized with Immunotherapy in Hepatocellular Carcinoma by Spatial Multi-omics ProfilingMai Chan Lau
869November 10, 2022
11:40 a.m. to 1:10 p.m.
NBTXR3-enhanced Proton Beam Immunoradiotherapy Reshapes Tumor Immune Microenvironment and Improves Abscopal Effect in an Anti-PD1-resistant Lung CancerYun Hu
899November 10, 2022
11:40 a.m. to 1:10 p.m.
BET Inhibitors Synergize with Anti-PD1 by Enhancing TCF7 Accessibility in Leukemiaderived Terminally Exhausted CD8+ T CellsKyle Romine
913November 10, 2022
11:40 a.m. to 1:10 p.m.
Translational Analysis of Advanced Metastatic Bladder Cancer Patients Treated With IO Combination Maveropepimut-S, Cyclophosphamide, and PembrolizumabHeather Torrey
923November 10, 2022
11:40 a.m. to 1:10 p.m.
Deep Single-cell, Proteogenomic Insights from SARS-CoV-2 Infected Lung Tissues Arutha Kulasinghe
951November 10, 2022
11:40 a.m. to 1:10 p.m.
Spatial Atlases of Immunological Development within the Lymph NodeTyler Hether
1151November 10, 2022
11:40 a.m. to 1:10 p.m.
Revealing Novel Therapeutic Indications through Profiling of Immune Modulatory Properties by UliledlimabYanni Zhang
1165November 10, 2022
11:40 a.m. to 1:10 p.m.
Impact of SD-101, a Toll-like Receptor 9 Class C (TLR9C), Agonist on Myeloid Derived Suppressor CellsChandra Ghosh
1169November 10, 2022
11:40 a.m. to 1:10 p.m.
Systemic Administration of TLR7/8 Agonist Micelles Triggers a Potent Anti-tumor Response Mediated by Neutrophils as Primary Effector Cells Followed by Establishment of an Immune Memory ResponseSimon Jensen
1173November 10, 2022
11:40 a.m. to 1:10 p.m.
ST101, a Peptide Antagonist of Novel I/O Target CEBPβ, Reprograms MDSC Polarization and Decreases Tumor-associated Tregs, Suggesting an Immune Component to Observed Clinical ResponsesClaudio Scuoppo
1337November 10, 2022
11:40 a.m. to 1:10 p.m.
Preclinical Evaluation of STAR0602, a Novel, First-in-class Anti-TCR Vb Targeted Bispecific Antibody with Potent Anti-tumor Activity for PD-1 Refractory Solid TumorsZhen Su
1451November 10, 2022
11:40 a.m. to 1:10 p.m.
The Impact of the Tumor Microenvironment on B Cell Infiltrate and Tertiary Lymphoid Structures in High Grade Serous Ovarian Cancer PatientsIan MacFawn
1467November 10, 2022
11:40 a.m. to 1:10 p.m.
An Holistic and Intergrated Approach for Investigating the Bacterial Microbiome, Gene Expression Profile and Immune Cell Profile in the Non-muscle Invasive Bladder Cancer Tumour MicroenvironmentTyler Wooldridge
1471November 10, 2022
11:40 a.m. to 1:10 p.m.
Pharmacodynamic and Predictive Biomarkers Associated with Response in Cancer Patients Treated with TPST-1120: A First-in-class, Small Molecule Antagonist of Peroxisome-proliferator Activated Receptor-AlphaNathan Standifer
76November 11, 2022
11:55 a.m. to 1:25 p.m.
NGS-based Immunology Panel: Applications in Preclinical Immuno-oncology ResearchJia Xue
102November 11, 2022
11:55 a.m. to 1:25 p.m.
Exploring the Spatial Heterogeneity of Immune Cells in Nasopharyngeal TumoursAastha Sobti
110November 11, 2022
11:55 a.m. to 1:25 p.m.
Characterization of HPV-specific T-cells in Blood and Tissue in Ugandan Women Living with HIV with Cervical Low Grade Squamous Intraepithelial LesionsAmy Codd
118November 11, 2022
11:55 a.m. to 1:25 p.m.
Delineation of Spatial Tissue Signatures of Immunotherapy Response Groups in Non-small Cell Lung Cancer (NSCLC)   Arutha Kulasinghe
142November 11, 2022
11:55 a.m. to 1:25 p.m.
Demonstrating the Role of Spatial Contexture in Determining Response to Immune Check Point Inhibitors Using a Tumor Histoculture PlatformSatish Sankaran
360November 11, 2022
11:55 a.m. to 1:25 p.m.
Novel Immunotherapy for Prostate Cancer Combining CAR T Cells and Myeloid Cell STAT3 InhibitionJohn Murad
390November 11, 2022
11:55 a.m. to 1:25 p.m.
Digital Spatial Profiling and Antigen-dependent Phenotypic Analysis of IL15-engineered Tumor-infiltrating Lymphocytes (CytoTIL15 Therapy) in an Allogeneic Melanoma PDX ModelRachel Burga
424November 11, 2022
11:55 a.m. to 1:25 p.m.
An Allosteric, Orally Administered CBL-B Inhibitor Remodels the Tumor Microenvironment and Enhances Immune-mediated Tumor Growth InhibitionYilin Qi
428November 11, 2022
11:55 a.m. to 1:25 p.m.
Diffusing Alpha-emitters Radiation Therapy Promotes a Pro-immunogenic Tumor Microenvironment and Synergizes with Pd-1 BlockadeSara Roumani
438November 11, 2022
11:55 a.m. to 1:25 p.m.
Interrogation of Immune Toxicity in Patients with Thymic Epithelial Tumors (TETS)Meredith McAdams
492November 11, 2022
11:55 a.m. to 1:25 p.m.
SIRPa Blockade Results in Tumor Intrinsic and Immune Microenviroment Effects Resulting in the Inhibition of Breast-to-brain MetastatsisElizabeth Stirling
504November 11, 2022
11:55 a.m. to 1:25 p.m.
PVRIG, a Novel T Cell Checkpoint, is Preferentially Expressed in TLS on Stem-like Memory T Cells, Potentially Inhibiting their ExpansionZoya Alteber
566November 11, 2022
11:55 a.m. to 1:25 p.m.
ENTPD1 as Predictive Marker of Treatment Response to Gemogenovatucel-T (Vigil) in Newly Diagnosed Ovarian CancerRodney Rocconi
610November 11, 2022
11:55 a.m. to 1:25 p.m.
Immune Biomarker Analysis of RP1 in Combination with Nivolumab in Patients with Advanced Solid TumorsKevin Harrington
720November 11, 2022
11:55 a.m. to 1:25 p.m.
Enhancing the Anti-tumor Immunity and Therapeutic Potential of ICT01, a Butyrophilin3A-targeted, γ9δ2 T Cell-activating Monoclonal Antibody, with Low Dose IL-2 in Patients with Advanced Solid Tumors: The Eviction-2 TrialJohann De Bono
784November 11, 2022
11:55 a.m. to 1:25 p.m.
Immune Profiling of Patients with Advanced Melanoma Intratumorally Treated with CV8102 as a Single-agent or in Combination with Anti-PD-1 Antibodies – Results of a Phase I Trial ExpansionMarina Gonzalez
840November 11, 2022
11:55 a.m. to 1:25 p.m.
Triple-drug Oral Immunotherapy Targeting Myeloid Cells for Treatment of Metastatic Osteosarcoma Evaluated in Spontaneous Canine ModelCheryl London
850November 11, 2022
11:55 a.m. to 1:25 p.m.
Interim Results for Phase 1B Dose Expansion of MTL-CEBPA in Combination with Pembrolizumab in Patients with Advanced Solid Tumour MalignanciesRuth Plummer
990November 11, 2022
11:55 a.m. to 1:25 p.m.
Heterogeneity in Glioblastoma Tumor Microenvironment: Strategies for Cancer-associated Fibroblast TargetingJonathan Stauber
1076November 11, 2022
11:55 a.m. to 1:25 p.m.
Anchored Immunotherapy with Intratumorally Administered Aluminum Hydroxide-tethered IL-12 Induces Potent Anti-tumor Immune ResponseSailaja Battula
1136November 11, 2022
11:55 a.m. to 1:25 p.m.
Induction of Tertiary Lymphoid Structures in Non-small Cell Lung Cancer Improves B and T Cell Anti-tumor ImmunityHye Mi Kim
1218November 11, 2022
11:55 a.m. to 1:25 p.m.
MSLN-targeted Immunotoxin LMB-100 Induces Development of Tertiary Lymphoid Structures and Tumor Regressions of Orthotopic MesotheliomaWenlong Liu
1316November 11, 2022
11:55 a.m. to 1:25 p.m.
A Novel Class of T Cell-activating Antibody that Selectively Targets the TCR B Chain to Promote Antitumor Activity through Activation and Expansion of a Novel, Polyclonal Effector Memory T Cell SubsetAndy Bayliffe
1340November 11, 2022
11:55 a.m. to 1:25 p.m.
BT7455, a Fully Synthetic Bicycle Tumor-targeted Immune Cell Agonist, Leads to Potent EphA2-dependent CD137 Agonism and Robust Anti-tumor EfficacyKristen Hurov
1356November 11, 2022
11:55 a.m. to 1:25 p.m.
Transcriptional Profiling of Bicycle Tumor-targeted CD137 Agonist-treated Mouse Tumors Revealed an Early and Rapid Activation of Myeloid Cells Followed by Infiltration of Cytotoxic T Cells into the TumorJohanna Lahdenranta
1430November 11, 2022
11:55 a.m. to 1:25 p.m.
The Immunological and Genomic Profiling of Colorectal and Breast Cancer Cell Lines can Distinguish Stem Like from Differentiated Tumor Cells: Implications for Cancer ImmunotherapyNeha Gopinath
1434November 11, 2022
11:55 a.m. to 1:25 p.m.
Interplay between the Tumour and Gut Microbiome and the Tumour Immune Microenvironment in Complete Responder Cancer PatientsNicola Annels
1448November 11, 2022
11:55 a.m. to 1:25 p.m.
Altered Myeloid Memory Function by BMP Signaling in Breast Cancer Bone MetastasesClaire Ihle
1454November 11, 2022
11:55 a.m. to 1:25 p.m.
Multiomics and Multimodal Analysis Approach to Construct a Diffuse Large B Cell Lymphoma Atlas of Tumor Microenvironment for Predictive ModelingMike Mattie
1456November 11, 2022
11:55 a.m. to 1:25 p.m.
Characterization of Inter and Intra Tumor Heterogeneity in Primary Melanoma and Melanoma Brain MetastasesAlberto Mendoza Valderrey
1458November 11, 2022
11:55 a.m. to 1:25 p.m.
Regulation of Neoantigen Specific T Cell Infiltration and Spatial Tumor Immune Architecture of Myeloma and its Premalignant PrecursorsNancy Villa
1468November 11, 2022
11:55 a.m. to 1:25 p.m.
First Data Readout of Standardized Transcriptional Profiling for Optimizing Cellular Therapies: A Multi-center PICI-NanoString CollaborationSarah Church
1478November 11, 2022
11:55 a.m. to 1:25 p.m.
A Phase I Study of Personalized Adoptive TCR T Cell Therapy in Patients with Solid Tumors: Safety, Efficacy, and T Cell Trafficking to Tumors of Non-virally Gene Edited T CellsSusan Foy